Synapse - David Kelsen

Results (537)

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial

Journal Article

Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
Lancet Oncology (2020)

Fulltext@MSK | Save

Development of a transgenic pig model of pancreatic cancer

Meeting Abstract

Boas, F.; Nurili, F.; Bendet, A.; Cheleuitte-Nieves, C.; Basturk, O.; Askan, G.; Monette, S.; Michel, A.; Schook, L.; Solomon, S.; more...
Journal of Vascular and Interventional Radiology (2020)

Fulltext@MSK | Save

Regorafenib in combination with first-line chemotherapy for metastatic esophagogastric cancer

Journal Article

Moy, R. H.; Dos Santos Fernandes, G.; Jonsson, P.; Chou, J. F.; Basunia, A.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
The Oncologist (2020)

Fulltext@MSK | Save

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma

Meeting Abstract

Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials

Journal Article

Ronellenfitsch, U.; Jensen, K.; Seide, S.; Kieser, M.; Schwarzbach, M.; Slanger, T. E.; Burmeister, B.; Kelsen, D.; Niedzwiecki, D.; Piessen, G.; more...
European Journal of Cancer (2019)

Fulltext@MSK | Save

Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC)

Meeting Abstract

Park, W.; Wong, W.; Yu, K. H.; Varghese, A. M.; Riaz, N.; Balachandran, V. P.; El Dika, I. H.; Raj, N. P.; Khalil, D.; Ku, G. Y.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma

Meeting Abstract

Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Total neoadjuvant chemo (ctx; TNT) for locally advanced gastric cancer (GC): The Memorial Sloan Kettering Cancer Center experience

Meeting Abstract

Greally, M.; Strong, V. E.; Yoon, S. S.; Coit, D. G.; Chou, J. F.; Capanu, M.; Kelsen, D. P.; Janjigian, Y. Y.; Ilson, D. H.; Ku, G. Y.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy